Parkinson's Disease - Drug Pipeline Landscape, 2023

Parkinson's Disease - Drug Pipeline Landscape, 2023

Parkinson's Disease (PD) simply called as Parkinson's, is a progressive neuro-degenerative disorder which mainly affects the motor systems due to the depletion in dopamine. The motor symptoms result from the death of cells in the substantia nigra leading to dopamine deficit. The cause of cell death involves the build-up of misfolded proteins into Lewy bodies in the neurons. Collectively known as Parkinsonian Syndrome.

The main cause of PD is not known. The environmental triggers, genetics are the associated factors in the cause of PD. Pesticides, herbicides and proximity to industrial plants, drugs are linked to the cause. The oxidation and generation of free radicals may be the cause of damage of thalamic nuclei.

The symptoms will slowly emerge. Early symptoms are tremors I hands, arms, legs and face, rigidity, slowness in the movement, difficulty walking, impaired balance and coordination. Other symptoms associated with cognitive and behavioural problems including depression, anxiety and apathy.

Parkinson's disease is diagnosed based on medical history and also based on signs and symptoms. Single-photon emission computerized tomography (SPECT) scan and dopamine transporter (DAT) scan helps in determining the disease. Imaging tests including MRI, CT and PET scans also helps in diagnosing the disease.

The main goal is to reduce PD symptoms. Treatment includes medications, surgery and physical treatment. The drugs that are helps in treating motor symptoms are dopa decarboxylase inhibitors, COMT inhibitor, dopamine agonists and MAO-B inhibitors. Late-stage PD requires psychiatric treatment. In final stage palliative care should be provided to improve person's quality of life.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the treatment of Parkinson’s Disease treatment such as ABBV-951, SPN-830, Buntanetap, E2027, and others. Key players involved in the development of therapies to treat Parkinson’s Disease are AbbVie, BenevolentAI, Novartis, Sumitomo Pharma and others. Two drugs are under late-stage Pre-registration, 30+ Phase III clinical trials and 10+ drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development.In Oct 2022, Supernus Pharmaceuticals Inc announced that the U.S. FDA has issued a complete Response Letter (CRL) for SPN-830 New Drug Application (NDA).

Report Highlights

Global Insight Service's, Parkinson's Disease - Drug Pipeline Landscape, 2023 report provides an overview of the Parkinson's Disease pipeline drugs. This report covers detailed insights on Parkinson's Disease drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Parkinson's Disease pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.


1. Introduction
1.1 Parkinson's Disease - Pipeline Drugs 2023 - Coverage
2 Disease Overview - Parkinson's Disease
2.1 Causes
2.2 Signs and Symptoms
2.3 Diagnosis
2.4 Disease Management
3 Parkinson's Disease - Pipeline Drugs Development - Overview
3.1 Comparative Analysis by Stage of Development
3.2 Number of Products under Development by Companies 2023
3.3 Products under Development by Companies 2023
4 Assessment of Therapeutics
4.1 Assessment by Target
4.2 Assessment by Mechanism of Action
4.3 Assessment by Molecule Type
4.4 Assessment by Route of Administration
5 Drug Profiles
5.1 Late-Stage Drugs - Pre-Registration
5.1.1 ABBV-951
5.2 Late-Stage Drugs - Filing Rejected
5.2.1 SPN-830
5.3 Clinical Stage Drugs - Phase III
5.3.1 BIIB122
5.3.2 Buntanetap
5.3.3 Dipraglurant
5.3.4 Exenatide
5.3.5 IPX203
5.3.6 LY03003
5.3.7 ND0612
5.3.8 Nortriptyline
5.3.9 P2B001
5.3.10 Safinamide
5.3.11 Tavapadon
5.4 Clinical Stage Drugs - Phase II
5.4.1 AAV-GAD
5.4.2 ACI-7104
5.4.3 AKST4290
5.4.4 AKST6021
5.4.5 Allo iPS Cell-Derived Dopamine Neural Progenitor
5.4.6 Ambroxol
5.4.7 AQW051
5.4.8 AV-101
5.4.9 AVP-923
5.4.10 AXO-Lenti-PD
5.4.11 Azathioprine
5.4.12 BEN-2001
5.4.13 BIA 28-6156
5.4.14 BLARCAMESINE
5.4.15 BTRX-246040
5.4.16 Bumetanide
5.4.17 Ceftriaxone
5.4.18 CNM-AU8
5.4.19 CPL500036
5.4.20 CST-103
5.4.21 CVN424
5.4.22 DA-9805
5.4.23 Dactolisib
5.4.24 Deferiprone
5.4.25 DLX313
5.4.26 E2027
5.4.27 ENT-01
5.4.28 EPI-589
5.4.29 Fosgonimeton
5.4.30 GM 608
5.4.31 GM608
5.4.32 GRF6021
5.4.33 HB-adMSC (allogenic)
5.4.34 HB-adMSC (Autologous)
5.4.35 HSG4112
5.4.36 IkT-148009
5.4.37 Iloperidone
5.4.38 INP107
5.4.39 INS-GSH
5.4.40 ION464
5.4.41 ION859
5.4.42 JM-010
5.4.43 K0706
5.4.44 KDT-3594
5.4.45 Ketamine
5.4.46 KW-6356
5.4.47 Lenrispodun
5.4.48 Levodopa Cyclops
5.4.49 Lixisenatide
5.4.50 Lurasidone hydrochloride
5.4.51 LY3884961
5.4.52 Mesdopetam
5.4.53 NBIb-1817
5.4.54 NE3107
5.4.55 Nilotinib
5.4.56 NLY01
5.4.57 NTCELL
5.4.58 NYX-458
5.4.59 Pirepemat
5.4.60 Prasinezumab
5.4.61 Radotinib
5.4.62 SAGE-718
5.4.63 SCC - 138
5.4.64 TAK-071
5.4.65 UCB0599
5.4.66 Ulotaront
5.4.67 WD-1603
5.4.68 Zuranolone
5.5 Clinical Stage Drugs - Phase I
5.5.1 Adipose-Derived Mesenchymal Stem Cells
5.5.2 AAV2-GDNF
5.5.3 ACI‑12589
5.5.4 AGX-201
5.5.5 AL101
5.5.6 Anle138b
5.5.7 AP-472
5.5.8 Apomorphine
5.5.9 ASN51
5.5.10 ATH434
5.5.11 BAN0805
5.5.12 BM306
5.5.13 CLE-600
5.5.14 CT-2500
5.5.15 CTC-413
5.5.16 Cu(II)ATSM
5.5.17 DNL201
5.5.18 DSP-6745
5.5.19 DSP-9632P
5.5.20 ESB1609
5.5.21 FB-101
5.5.22 GM1
5.5.23 HEC122505MsOH
5.5.24 HNC364
5.5.25 Human FGF-1
5.5.26 KM-819
5.5.27 Lu AE04621
5.5.28 Lu AF28996
5.5.29 Lu AF82422
5.5.30 LY03009
5.5.31 MEDI1341
5.5.32 MSK-DA01
5.5.33 NBTX-001
5.5.34 NPT088
5.5.35 NPT520-34
5.5.36 OK99
5.5.37 Phenlarmide
5.5.38 PK081
5.5.39 Pramipexole
5.5.40 PXS-4728
5.5.41 Renzapride
5.5.42 RP5063
5.5.43 SBT-272
5.5.44 SER-214
5.5.45 Talineuren
5.5.46 Tau Aggregation Inhibitors
5.5.47 TPU-002
5.5.48 Tricaprilin
5.5.49 TWB-201
5.5.50 UB-312
5.5.51 UCB0022
5.5.52 UCB7853
5.5.53 Valiloxybate
5.5.54 WIT-2001
5.5.55 XC130
5.5.56 YTX-7739
5.6 Clinical Stage Drugs - Phase 0
5.6.1 hAESCs
5.7 Early-Stage Drugs - IND/CTA Filed
5.7.1 PRAX-944
5.7.2 S2212237
5.7.3 Sodium Oligomannate
5.8 Early-Stage Drugs - Preclinical
5.9.1 2nd Lead development candidate
5.9.2 AB-5006
5.9.3 ABL301
5.9.4 ACD856
5.9.5 ACT-02
5.9.6 ADD485002
5.9.7 AEV003
5.9.8 AGT-110
5.9.9 AGT-115
5.9.10 AGT-190
5.9.11 AIM Biologicals
5.9.12 AL00804
5.9.13 ALA-4000
5.9.14 AlloRx
5.9.15 Alpha synuclein
5.9.16 Alpha-Syn Degrader
5.9.17 Alpha-Synuclein
5.9.18 Alpha-Synuclein Oligomer Inhibitor
5.9.19 ALS205
5.9.20 AMT-210
5.9.21 AN317
5.9.22 ANPD001
5.9.23 Anti‑a‑syn antibody
5.9.24 Armesocarb
5.9.25 ARN-1104
5.9.26 ASD-005
5.9.27 ASHA-091
5.9.28 ASN90
5.9.29 AST-009
5.9.30 ATH-399A
5.9.31 AZ001
5.9.32 BIA-29
5.9.33 BIA-30
5.9.34 BIA-31
5.9.35 BIA-32
5.9.36 BSC-3201
5.9.37 CADI-T3021
5.9.38 Cathepsin A Inhibitor
5.9.39 CB101
5.9.40 CDNF protein
5.9.41 CP-012
5.9.42 CRB-113
5.9.43 C-terminal alpha synuclein
5.9.44 CVN398
5.9.45 D4
5.9.46 Dopaminergic Neurons
5.9.47 EHP-102
5.9.48 FANA Antisense Oligonucleotides
5.9.49 FB418
5.9.50 FHL-101
5.9.51 FHL-201
5.9.52 FHL-401
5.9.53 FHL-501
5.9.54 FHL-701
5.9.55 FHL-801
5.9.56 FMD-NPC
5.9.57 GBA1 related Parkinson's Disease
5.9.58 GDF5
5.9.59 GDNF
5.9.60 Gene Therapy for Parkinson's Disease
5.9.61 Glunomab
5.9.62 GRE 213
5.9.63 GT-02287
5.9.64 HBI-002
5.9.65 HER-096
5.9.66 Icapamespib
5.9.67 iCP-Parkin
5.9.68 ID119040338
5.9.69 IPX203
5.9.70 ISC-hpNSC
5.9.71 KP405
5.9.72 LAUR-101
5.9.73 Lead Development Candidate
5.9.74 LRRK2 Inhibitor
5.9.75 LRRK2 kinase inhibitors
5.9.76 MD-049
5.9.77 MDH-014
5.9.78 MDH-244
5.9.79 METI-204
5.9.80 mGlu4 PAM
5.9.81 MIN-301
5.9.82 MIT-003
5.9.83 Mitometin
5.9.84 MP201
5.9.85 MPP+
5.9.86 mPTP Inhibitor
5.9.87 MRx0005
5.9.88 MRx0029
5.9.89 MSC-NTF cells
5.9.90 MT101
5.9.91 MT2
5.9.92 MTK-458
5.9.93 Mutant LRRK2
5.9.94 NB001
5.9.95 NB129
5.9.96 NC-B8
5.9.97 Neuro I
5.9.98 NLY02
5.9.99 NM-101
5.9.100 NN001
5.9.101 NNI-362
5.9.102 NNI-370
5.9.103 NNZ-2591
5.9.104 NOX Inhibitor
5.9.105 NWL-283
5.9.106 NXP031
5.9.107 Opmized Therapeuc Mixtures (OTMs)
5.9.108 OxyGCase
5.9.109 p53 Inducible Gene 3 (PIG3) Modulator
5.9.110 Parkin Activators
5.9.111 PBI-05204
5.9.112 PCT-3012
5.9.113 PDSTEM
5.9.114 PIKE-PARK
5.9.115 PP-003
5.9.116 PPI-1011
5.9.117 PRI-100
5.9.118 Pridopidine
5.9.119 Program 1
5.9.120 Program 2
5.9.121 PSW001
5.9.122 PV-1950
5.9.123 Regenerative Therapeutics for Parkinson's Disease
5.9.124 Resiniferatoxin
5.9.125 RNS60
5.9.126 SAGE-324
5.9.127 SB623
5.9.128 scp791
5.9.129 SER-252
5.9.130 SHX-018
5.9.131 SLS-004
5.9.132 SLS-007
5.9.133 Small Molecules for Parkinson's Disease
5.9.134 SNP201
5.9.135 SP-420
5.9.136 ST-502
5.9.137 StabiliC
5.9.138 Stem Cell Agency's
5.9.139 Stem Cell Therapy for Parkinson's Disease
5.9.140 STL-101
5.9.141 Synthetic GM1 ganglioside
5.9.142 Target 6-20+
5.9.143 TBP201
5.9.144 TDP-43
5.9.145 TED-A9
5.9.146 TEV-56287
5.9.147 TF0068
5.9.148 TMEM175
5.9.149 Tolerogenic Dendritic Cells
5.9.150 TQS-621
5.9.151 Trans sodium crocetinate
5.9.152 TrkB and TrkC Activator
5.9.153 Trophoblast Glycoprotein (Tpbg)
5.9.154 TRPML1
5.9.155 Tryptophan 23-dioxygenase (TDO)
5.9.156 TTX-001
5.9.157 TZ-113
5.9.158 USP30 Inhibitor
5.9.159 WID-2101
5.9.160 WT-LRRK2
5.9.161 XS-001
5.9 Early-Stage Drugs - Discovery
5.9.1 1ST-103
5.9.2 1ST-105
5.9.3 ABXY-1
5.9.4 ABXY-3
5.9.5 AKO004
5.9.6 Alpha synuclein
5.9.7 Alpha-Synuclein
5.9.8 ANL-103
5.9.9 ANPD002
5.9.10 AST-301
5.9.11 BRLVV
5.9.12 Cell Therapy for Parkinson's Disease
5.9.13 CM-PK
5.9.14 Dopaminergic Neurons
5.9.15 Drug for Parkinson's Disease
5.9.16 Drug for Parkinson's disease
5.9.17 Drug for Parkinson's disease
5.9.18 Drug for Parkinson's Disease
5.9.19 Drug for Parkinson's Disease
5.9.20 Drug for Parkinson's Disease
5.9.21 Drug for Parkinson's Disease
5.9.22 DUB Targets
5.9.23 ET-101
5.9.24 Follow-up Compound
5.9.25 Gene Therapy for Parkinson's Disease
5.9.26 Gene Therapy for Parkinson's Disease
5.9.27 Glucocerebrosidase (Gcase)
5.9.28 hEN1 for Parkinson's Disease
5.9.29 hNPC-03
5.9.30 IC 100
5.9.31 LB-P4
5.9.32 LD01019
5.9.33 Long-Acting Release Injectable
5.9.34 LRRK2
5.9.35 LRRK2 agonists
5.9.36 LRRK2 Interaction Program
5.9.37 Lysosomal Channel 1
5.9.38 Lysosomal channel 2
5.9.39 Morphomer a‑syn Aggregation Inhibitor
5.9.40 NB003
5.9.41 NBD-05
5.9.42 Nic Alpha 6 Program
5.9.43 NM-301
5.9.44 NM-401
5.9.45 NRDN-201
5.9.46 Organotherapeutics
5.9.47 PD Dementia
5.9.48 PD1601
5.9.49 PD1602
5.9.50 PD-A
5.9.51 Peptide for Parkinson's Disease
5.9.52 PINK1
5.9.53 PN001
5.9.54 PN002
5.9.55 PN003
5.9.56 PRG-CNS-3
5.9.57 Program 1
5.9.58 Program 2
5.9.59 Program 3
5.9.60 PRX303
5.9.61 PSY-01
5.9.62 RNAi Therapeutics for Parkinson's Disease
5.9.63 SARM1 inhibitors
5.9.64 Sigma-2 Receptor Modulator
5.9.65 Small Molecule for Parkinson Disease
5.9.66 Small Molecule Potassium Channel Type 13 (Kv13) Blockers
5.9.67 Small Molecules for Parkinson's Disease
5.9.68 Small Molecules for Parkinson's Disease
5.9.69 Small-Molecule Therapeutics for Parkinson's Disease
5.9.70 SNP614
5.9.71 SOL-368
5.9.72 Soluble Epoxide Hydrolase (sEH) Inhibitors
5.9.73 Stem Cell Therapy
5.9.74 STL-201
5.9.75 Target-18
5.9.76 TE-NSP
5.9.77 TMEM175 Interaction Program
5.9.78 Undisclosed Interaction target
5.9.79 VVZ-E2
5.9.80 xB3-007
5.9.81 YH36425
5.10 Unknown Stage Drugs
5.10.1 JBPOS0101
5.10.2 MCP-311
6 Key Deals
7 Key Regulatory Designations
8 Key Upcoming Milestones
9 Key Companies Involved
9.1 1ST Biotherapeutics Inc
9.2 2N Pharma ApS
9.3 3Z ehf
9.4 4D Pharma Plc
9.5 Abaxys Therapeutics SA
9.6 AbbVie
9.7 Abfero Pharmaceuticals Inc
9.8 ABL Bio Inc
9.9 AC Immune SA
9.10 Accure Therapeutics SL
9.11 AceLink Therapeutics Inc
9.12 Acelot Inc
9.13 AcureX Therapeutics Corp
9.14 Addex Pharma SA
9.15 Adhera Therapeutics Inc
9.16 Adicet Bio Inc
9.17 Aeterna Zentaris Inc
9.18 AevisBio Inc
9.19 AgoneX Biopharmaceuticals Inc
9.20 Akome Biotech Ltd
9.21 Alan Laboratories Inc
9.22 Alar Pharmaceuticals Inc
9.23 Alector Inc
9.24 Alexza Pharmaceuticals Inc
9.25 Alkahest Inc
9.26 Alsonex Pty Ltd
9.27 Alterity Therapeutics Ltd
9.28 AltPep Corp
9.29 AlzeCure Pharma AB
9.30 Amathus Therapeutics Inc
9.31 Amneal Pharmaceuticals Inc
9.32 Anavex Life Sciences Corp
9.33 ANLBio Co Ltd
9.34 Annovis Bio Inc
9.35 ApoPharma Inc
9.36 Appello Pharmaceuticals Inc
9.37 Aprinoia Therapeutics Inc
9.38 AptaBio Therapeutics Inc
9.39 Aptamer Sciences Inc
9.40 Aptinyx Inc
9.41 ArmaGen Inc
9.42 Arrien Pharmaceuticals LLC
9.43 Artizan Biosciences Inc
9.44 Arvinas Inc
9.45 Asceneuron SA
9.46 Asdera LLC
9.47 Asha Therapeutics LLC
9.48 Asklepios BioPharmaceutical Inc
9.49 Aspen Neuroscience Inc
9.50 AstraZeneca
9.51 Astrogen Ltd
9.52 Atalanta Therapeutics Inc
9.53 Athira Pharma Inc
9.54 Atlantic Healthcare Plc
9.55 AUM LifeTech Inc
9.56 Autifony Therapeutics Ltd
9.57 Avanir Pharmaceuticals Inc
9.58 Axial Therapeutics Inc
9.59 Azymus Therapeutics Inc
9.60 B&A Therapeutics
9.61 Beech Tree Labs Inc
9.62 Belief Biomed Inc
9.63 BenevolentAI Bio
9.64 Berg LLC
9.65 Bial - Portela & Ca SA
9.66 BioArctic AB
9.67 Bioasis Technologies Inc
9.68 Biogen
9.69 Bio-Modeling Systems SAS
9.70 Bio-Pharm Solutions Co Ltd
9.71 BioVie Inc
9.72 Bisichem Co Ltd
9.73 BlackThorn Therapeutics Inc
9.74 Blue Therapeutics Inc
9.75 BlueRock Therapeutics
9.76 BrainEver SAS
9.77 BrainStorm Cell Therapeutics Inc
9.78 BrainX Corp
9.79 Cantabio Pharmaceuticals Inc
9.80 Caraway Therapeutics Inc
9.81 Casma Therapeutics Inc
9.82 Celavie Biosciences LLC
9.83 Celeris Therapeutics Inc
9.84 Cellivery Therapeutics Inc
9.85 Celon Pharma SA
9.86 Celros Biotech Co Ltd
9.87 Cerecin Pte Ltd
9.88 Cerevance
9.89 Cerevel Therapeutics
9.90 CHA Biotech Co Ltd
9.91 Chase Therapeutics
9.92 Chimerna Therapeutics Inc
9.93 Circadian Therapeutics
9.94 Clene Nanomedicine
9.95 Clexio Biosciences Ltd
9.96 Cognition Therapeutics Inc
9.97 Collaborative Medicinal Development LLC
9.98 Contera Pharma ApS
9.99 CuraSen Therapeutics Inc
9.100 Cure Parkinson
9.101 Curemark LLC
9.102 CuroNZ Ltd
9.103 DanPET AB
9.104 Denali Therapeutics
9.105 Diffusion Pharmaceuticals Inc
9.106 Dong-A ST Co Ltd
9.107 Easywell Biomedical Inc
9.108 EHL Bio Co Ltd
9.109 Eikonoklastes Therapeutics Inc
9.110 Eisai Co Ltd
9.111 Eli Lilly and Co
9.112 EmendoBio Inc
9.113 Emerald Health Sciences Inc
9.114 ENCEFA
9.115 Enterin Inc
9.116 Enveda Biosciences Inc
9.117 E-scape Bio Inc
9.118 Exegenesis Bio Inc
9.119 F Hoffmann-La Roche AG
9.120 FibroGenesis LLC
9.121 Forest Hills Partners Hong Kong Ltd
9.122 Gain Therapeutics
9.123 Gateway Institute for Brain Research
9.124 GB Sciences Inc
9.125 Genervon Biopharmaceuticals LLC
9.126 Glaceum Inc
9.127 GraySpace Therapeutics Inc
9.128 Grespo AB
9.129 Guangzhou Dazhou Biomedicine
9.130 Guangzhou Henovcom Bioscience Co Ltd
9.131 H. Lundbeck A/S
9.132 Halia Therapeutics Inc
9.133 Help Therapeutics
9.134 Herantis Pharma Plc
9.135 Hillhurst Biopharmaceuticals Inc
9.136 Hope Biosciences
9.137 Hopstem Biotechnology LLC
9.138 Ibex Biosciences LLC
9.139 ICB International Inc
9.140 Icure Pharmaceutical Inc
9.141 Ildong Pharmaceutical Co Ltd
9.142 Il-Yang Pharm Co Ltd
9.143 Impel Pharmaceuticals Inc
9.144 Inhibikase Therapeutics
9.145 Innervace Inc
9.146 InnoMedica Schweiz AG
9.147 Integrative Research Laboratories AB
9.148 International Stem Cell Corp
9.149 Intra-Cellular Therapies Inc
9.150 Ionis Pharmaceuticals Inc
9.151 iRegene Therapeutics Co Ltd
9.152 Jeil Pharmaceutical Co Ltd
9.153 Kainos Medicine Inc
9.154 Kallyope Inc
9.155 Kariya Pharmaceuticals IVS
9.156 KeifeRx LLC
9.157 Kissei Pharmaceutical Co Ltd
9.158 Kyowa Kirin Co Ltd
9.159 Lauren Sciences LLC
9.160 Lead Discovery Center GmbH
9.161 LES LABORATOIRES SERVIER
9.162 LISCure Biosciences Co Ltd
9.163 Living Cell Technologies
9.164 Luye Pharma Group
9.165 Lys Therapeutics SAS
9.166 MD Healthcare Inc
9.167 MeiraGTx Holdings Plc
9.168 Mercaptor Discoveries Inc
9.169 MetiMedi Pharmaceuticals Co Ltd
9.170 MimeTech Srl
9.171 Minerva Neurosciences Inc
9.172 Mission Therapeutics Ltd
9.173 Mitochon Pharmaceuticals Inc
9.174 MitoImmune Therapeutics Inc
9.175 Mitokinin LLC
9.176 Modag
9.177 MThera Pharma Co Ltd
9.178 Muna Therapeutics ApS
9.179 Nanomerics Ltd
9.180 Netherlands Translational Research Center BV
9.181 NeuExcell Therapeutics Inc
9.182 Neuraly Inc
9.183 Neuramedy Co Ltd
9.184 Neuren Pharmaceuticals Ltd
9.185 NeuroDerm Ltd
9.186 Neurodon LLC
9.187 Neuron23 Inc
9.188 Neurona Therapeutics Inc
9.189 NeuroNascent Inc
9.190 NeuroPn Therapeutics LLC
9.191 Neuropore Therapies Inc
9.192 NeuroSense Therapeutics Ltd
9.193 New World Laboratories Inc
9.194 Newron Pharmaceuticals SPA
9.195 Nexmos Inc
9.196 Nine Square Therapeutics Inc
9.197 Nobilis Therapeutics Inc
9.198 Nostrum Biodiscovery SL
9.199 Notitia Biotechnologies
9.200 Novartis AG
9.201 Novo Nordisk AS
9.202 NTZ Lab Ltd
9.203 Nuravax Inc
9.204 NurrOn Pharmaceuticals Inc
9.205 NysnoBio LLC
9.206 Occamz Razor
9.207 Oxyrane Belgium NV
9.208 Parkure Ltd
9.209 Pharma Two B
9.210 PharmaKure Ltd
9.211 PharmaTher Holdings Ltd
9.212 PharmatrophiX Inc
9.213 Pharmaxis Ltd
9.214 Phoenix Biotechnology Inc
9.215 Pike Therapeutics Inc
9.216 PolyCore Therapeutics LLC
9.217 Praxis Precision Medicines Inc
9.218 Prazer Therapeutics
9.219 PRG S&Tech Inc
9.220 Priavoid GmbH
9.221 Prilenia Therapeutics Development Ltd
9.222 Primary Peptides Inc
9.223 Proclara Biosciences Inc
9.224 Progenra Inc
9.225 Prosetta Biosciences Inc
9.226 Psy Therapeutics Inc
9.227 PureIMS BV
9.228 Revalesio Corp
9.229 Reviva Pharmaceuticals Inc
9.230 SBiomedics Co Ltd
9.231 Sage Therapeutics Inc
9.232 Samus Therapeutics Inc
9.233 SanBio Co Ltd
9.234 Sangamo Therapeutics
9.235 Saniona AB
9.236 SciNeuro Pharmaceuticals
9.237 SeaBeLife Spas
9.238 Seelos Therapeutics Inc
9.239 Seneb BioSciences Inc
9.240 Serina Therapeutics
9.241 Shanghai Green Valley Pharmaceutical Co Ltd
9.242 Shanghai iCELL Biotechnology Co Ltd
9.243 Shanghai Leado Pharmaceutical Technology Co Ltd
9.244 Shanghai WD Pharmaceutical Co Ltd
9.245 Shape Therapeutics Inc
9.246 Shijiazhuang Yiling Pharmaceutical Co Ltd
9.247 Silver Creek Pharmaceuticals Inc
9.248 Sinfonia Biotherapeutics Inc
9.249 Sinopia Biosciences Inc
9.250 Sio Gene Therapies Inc
9.251 SOLA Biosciences LLC
9.252 Sorrento Therapeutics Inc
9.253 SQZ Biotechnologies Co
9.254 Stealth BioTherapeutics Corp
9.255 Stellate Therapeutics Inc
9.256 Sumitomo Pharma Co Ltd
9.257 Sun Pharmaceutical Industries Ltd
9.258 Sun Pharma Advanced Research Company Ltd
9.259 Sunshine Lake Pharma Co Ltd
9.260 Supernus Pharmaceuticals Inc
9.261 Synaptogenix Inc
9.262 Synthonics Inc
9.263 Taiwan Mitochondrion Applied Technology CoLtd
9.264 Takeda Pharmaceutical Co Ltd
9.265 TauRx Therapeutics Ltd
9.266 Techfields Pharma Co Ltd
9.267 TechnoPhage SA
9.268 Teikoku Pharma USA Inc
9.269 Tessara Therapeutics Pty Ltd
9.270 Teva Pharmaceutical Industries Ltd
9.271 Therapeutic Solutions International Inc
9.272 Trailhead Biosystems Inc
9.273 Tranquis Therapeutics Inc
9.274 TreeFrog Therapeutics SAS
9.275 Treventis Corp
9.276 UCB Biopharma SRL
9.277 UniQure NV
9.278 VANDA PHARMACEUTICALS
9.279 Vanqua Bio Inc
9.280 Vaxxinity
9.281 Verge Genomics
9.282 Vincere Biosciences Inc
9.283 Vistagen Therapeutics Inc
9.284 Vitro Biopharma Inc
9.285 Vivifi Biotech Ltd
9.286 Vivozon Inc
9.287 Voyager Therapeutics Inc
9.288 Vyant Bio Inc
9.289 Whan In Pharm Co Ltd
9.290 Wren Therapeutics Ltd
9.291 XellSmart Biomedical (Shanghai) Co Ltd
9.292 Xoc Pharmaceuticals
9.293 XWPharma
9.294 Yuhan Corp
9.295 Yumanity Therapeutics Inc
9.296 Zhittya Genesis Medicine Inc
9.297 ZyVersa Therapeutics Inc
10 Dormant Drugs
10.1 Inactive Drugs
10.2 Discontinued Drugs
11 Appendix
List of Tables
Table 1 2 Number of Products under Development by Companies
Table 1 3 Products under Development by Companies
Table 1 4 Products by Targets
Table 1 5 Products by Mechanism of Action
Table 1 6 Products by Molecule Type
Table 1 7 Products by Route of Administration
Table 2.1 Clinical Trial Details - BIIB122/Biogen
Table 2.2 Clinical Trial Details - Buntanetap/Annovis Bio Inc
Table 2.3 Clinical Trial Details - Exenatide/Cure Parkinson
Table 2.4 Clinical Trial Details - IPX203 /Amneal Pharmaceuticals LLC
Table 2.5 Clinical Trial Details - LY03003/Luye Pharma Group
Table 2.6 Clinical Trial Details - ND0612/NeuroDerm Ltd
Table 2.7 Clinical Trial Details - Nortriptyline/Cure Parkinson
Table 2.8 Clinical Trial Details - P2B001 /Pharma Two B
Table 2.9 Clinical Trial Details - Safinamide/Newron Pharmaceuticals SPA
Table 2.10 Clinical Trial Details - Tavapadon/Cerevel Therapeutics
Table 2.11 Clinical Trial Details - AKST4290/Alkahest Inc
Table 2.12 Clinical Trial Details - AKST6021/Alkahest Inc
Table 2.13 Clinical Trial Details - Ambroxol/Cure Parkinson
Table 2.14 Clinical Trial Details - AQW051/Novartis AG
Table 2.15 Clinical Trial Details - AV-101/Vistagen Therapeutics Inc
Table 2.16 Clinical Trial Details - AVP-923/Avanir Pharmaceuticals Inc
Table 2.17 Clinical Trial Details - BEN-2001/BenevolentAI Bio
Table 2.18 Clinical Trial Details - BIA 28-6156/Bial - Portela & Ca SA
Table 2.19 Clinical Trial Details - BLARCAMESINE/ Anavex Life Sciences Corp
Table 2.20 Clinical Trial Details - BTRX-246040/BlackThorn Therapeutics Inc
Table 2.21 Clinical Trial Details - Bumetanide/B&A Therapeutics
Table 2.22 Clinical Trial Details - Ceftriaxone/BrainX Corp
Table 2.23 Clinical Trial Details - CNM-AU8/Clene Nanomedicine
Table 2.24 Clinical Trial Details - CPL500036/Celon Pharma SA
Table 2.25 Clinical Trial Details - CST-103/CuraSen Therapeutics Inc
Table 2.26 Clinical Trial Details - CVN424/Cerevance
Table 2.27 Clinical Trial Details - DA-9805/Dong-A ST Co Ltd
Table 2.28 Clinical Trial Details - Deferiprone/ApoPharma Inc
Table 2.29 Clinical Trial Details - E2027/Eisai Co Ltd
Table 2.30 Clinical Trial Details - ENT-01/Enterin Inc
Table 2.31 Clinical Trial Details - EPI-589/Sumitomo Pharma Co Ltd
Table 2.32 Clinical Trial Details - Fosgonimeton/Athira Pharma Inc
Table 2.33 Clinical Trial Details - GM 608/Genervon Biopharmaceuticals LLC
Table 2.34 Clinical Trial Details - HB-adMSC (allogenic)/Hope Biosciences
Table 2.35 Clinical Trial Details - HB-adMSC (Autologous)/Hope Biosciences
Table 2.36 Clinical Trial Details - IkT-148009/Inhibikase Therapeutics
Table 2.37 Clinical Trial Details - Iloperidone/VANDA PHARMACEUTICALS
Table 2.38 Clinical Trial Details - INP107 /Impel Pharmaceuticals Inc
Table 2.39 Clinical Trial Details - INS-GSH/Gateway Institute for Brain Research
Table 2.40 Clinical Trial Details - ION464/Ionis Pharmaceuticals Inc
Table 2.41 Clinical Trial Details - ION859/Ionis Pharmaceuticals Inc
Table 2.42 Clinical Trial Details - JM-010/Contera Pharma
Table 2.43 Clinical Trial Details - K0706/Sun Pharma Advanced Research Company Ltd
Table 2.44 Clinical Trial Details - KDT-3594/Kissei Pharmaceutical Co Ltd
Table 2.45 Clinical Trial Details - KW-6356/Kyowa Kirin Co Ltd
Table 2.46 Clinical Trial Details - Lenrispodun/Intra-Cellular Therapies Inc
Table 2.47 Clinical Trial Details - Lixisenatide/Cure Parkinson
Table 2.48 Clinical Trial Details - LY3884961/Eli Lilly and Co
Table 2.49 Clinical Trial Details - Mesdopetam/Integrative Research Laboratories AB
Table 2.50 Clinical Trial Details - NBIb-1817/Voyager Therapeutics Inc
Table 2.51 Clinical Trial Details - NE3107 /BioVie Inc
Table 2.52 Clinical Trial Details - NLY01/Neuraly Inc
Table 2.53 Clinical Trial Details - NYX-458/Aptinyx Inc
Table 2.54 Clinical Trial Details - Pirepemat/Integrative Research Laboratories AB
Table 2.55 Clinical Trial Details - Prasinezumab/F. Hoffmann-La Roche AG
Table 2.56 Clinical Trial Details - Radotinib /Il-Yang Pharm Co Ltd
Table 2.57 Clinical Trial Details - SAGE-718/Sage Therapeutics Inc
Table 2.58 Clinical Trial Details - UCB0599/UCB Biopharma SRL
Table 2.59 Clinical Trial Details - Ulotaront/Sumitomo Pharma Co Ltd
Table 2.60 Clinical Trial Details - WD-1603/Shanghai WD Pharmaceutical Co Ltd
Table 2.61 Clinical Trial Details - Zuranolone/Sage Therapeutics Inc
Table 2.62 Clinical Trial Details - Adipose-Derived Mesenchymal Stem Cells/Taiwan Mitochondrion Applied Technology Co Ltd
Table 2.63 Clinical Trial Details - AAV2-GDNF/Asklepios BioPharmaceutical Inc
Table 2.64 Clinical Trial Details - Anle138b/Modag
Table 2.65 Clinical Trial Details - Apomorphine/Alexza Pharmaceuticals, Inc
Table 2.66 Clinical Trial Details - Cu(II)ATSM/Collaborative Medicinal Development LLC
Table 2.67 Clinical Trial Details - DNL201/Denali Therapeutics
Table 2.68 Clinical Trial Details - FB-101/1ST Biotherapeutics Inc
Table 2.69 Clinical Trial Details - HEC122505MsOH/Sunshine Lake Pharma Co Ltd
Table 2.70 Clinical Trial Details - HNC364/Guangzhou Henovcom Bioscience Co Ltd
Table 2.71 Clinical Trial Details - Human FGF-1/Zhittya Genesis Medicine Inc
Table 2.72 Clinical Trial Details - Lu AE04621/H. Lundbeck A/S
Table 2.73 Clinical Trial Details - Lu AF28996/H. Lundbeck A/S
Table 2.74 Clinical Trial Details - Lu AF82422/H. Lundbeck A/S
Table 2.75 Clinical Trial Details - LY03009/Luye Pharma Group
Table 2.76 Clinical Trial Details - MEDI1341/AstraZeneca
Table 2.77 Clinical Trial Details - MSK-DA01/BlueRock Therapeutics
Table 2.78 Clinical Trial Details - NBTX-001/Nobilis Therapeutics Inc
Table 2.79 Clinical Trial Details - NPT520-34/Neuropore Therapies Inc
Table 2.80 Clinical Trial Details - OK99 /Celavie Biosciences LLC
Table 2.81 Clinical Trial Details - Phenlarmide/Shijiazhuang Yiling Pharmaceutical Co Ltd
Table 2.82 Clinical Trial Details - Talineuren/InnoMedica Schweiz AG
Table 2.83 Clinical Trial Details - UB-312/Vaxxinity
Table 2.84 Clinical Trial Details - UCB0022 /UCB Biopharma SRL
Table 2.85 Clinical Trial Details - UCB7853/UCB Biopharma SRL
Table 2.86 Clinical Trial Details - Valiloxybate/XWPharma
Table 2.87 Clinical Trial Details - XC130/Xoc Pharmaceuticals
Table 2.88 Clinical Trial Details - hAESCs/Shanghai iCELL Biotechnology Co Ltd
Table 3. 1 Regulatory Designations
Table 4. 1 Inactive Drugs
Table 4. 2 Discontinued Drugs
List of Figures
Figure 1. 1 Number of Products under Development for Parkinson's Disease 2023
Figure 1. 2 Products by Top 5 Targets and Stage of Development for Parkinson's Disease 2023
Figure 1. 3 Products by Top 5 Mechanism of Action and Stage of Development for Parkinson's Disease 2023
Figure 1. 4 Products by Top 5 Molecule Type and Stage of Development for Parkinson's Disease 2023
Figure 1. 5 Products by Top 5 Route of Administration and Stage of Development for Parkinson's Disease 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings